Literature DB >> 2522842

The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans.

J A Schifferli1, Y C Ng, J P Paccaud, M J Walport.   

Abstract

Defective clearance of immune complexes (IC) may contribute to the pathogenesis of diseases such as SLE. We studied the effect of hypocomplementaemia and the influence of erythrocyte complement receptor type 1 (CR1, CD35) number on the clearance of radiolabelled tetanus toxoid (TT)-anti-TT IC from the circulation. These were injected intravenously into 9 normal subjects and 15 patients with diseases characterized by IC formation and/or hypocomplementemia, including 2 with hereditary complement deficiency. IC were found to bind to erythrocyte CR1 in a complement-dependent manner and their degree of uptake was directly correlated with CR1 numbers. Two phases of IC clearance were identified. The first was rapid, occurring within 1 min. Since this phase might represent inappropriate deposition of IC in target organs we called it trapping. It was seen predominantly in subjects with low CR1, low complement, and low binding of complexes to red cells. The second phase was monoexponential with a mean elimination rate of 14.1%/min; it was inversely correlated with CR1 numbers and binding of complexes to red cells. In a second study each individual was injected with IC bound to autologous erythrocytes in vitro using normal serum so that the effects of complement deficiency were eliminated. Up to 81.4% of these bound IC were released in vivo from erythrocytes in 1 min, and the proportion was inversely correlated with CR1 numbers. Only five patients showed trapping, and these had low CR1 numbers and high percentage release of IC. The second phase of elimination was inversely correlated with CR1 numbers and the proportion of IC remaining bound to red cells at 1 min. The two complement-deficient patients had normal CR1: when IC were injected, trapping and very fast clearance rates were observed; however complexes that had been opsonized and bound to erythrocytes were cleared at a slower rate without evidence for trapping. These studies show that complement and erythrocyte CR1 may determine the physiological clearance of certain types of IC and suggest that this system may function abnormally when CR1 number or complement function are reduced.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522842      PMCID: PMC1541944     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

Review 1.  The role of complement and its receptor in the elimination of immune complexes.

Authors:  J A Schifferli; Y C Ng; D K Peters
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

2.  Saturation of the reticuloendothelial system with soluble immune complexes.

Authors:  A O Haakenstad; M Mannik
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

3.  Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli.

Authors:  F J Waxman; L A Hebert; F G Cosio; W L Smead; M E VanAman; J M Taguiam; D J Birmingham
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

4.  Primate erythrocyte-immune complex-clearing mechanism.

Authors:  J B Cornacoff; L A Hebert; W L Smead; M E VanAman; D J Birmingham; F J Waxman
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

5.  Complement depletion accelerates the clearance of immune complexes from the circulation of primates.

Authors:  F J Waxman; L A Hebert; J B Cornacoff; M E VanAman; W L Smead; E H Kraut; D J Birmingham; J M Taguiam
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases.

Authors:  M M Frank; T J Lawley; M I Hamburger; E J Brown
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

8.  Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Authors:  G D Ross; W J Yount; M J Walport; J B Winfield; C J Parker; C R Fuller; R P Taylor; B L Myones; P J Lachmann
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  Abnormal clearance of soluble aggregates of human immunoglobulin G in patients with systemic lupus erythematosus.

Authors:  S Lobatto; M R Daha; F C Breedveld; E K Pauwels; J H Evers-Schouten; A A Voetman; A Cats; L A Van Es
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

10.  Clearance of circulating DNA-anti-DNA immune complexes in mice.

Authors:  W Emlen; M Mannik
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  28 in total

1.  Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE).

Authors:  I Csípö; E Kiss; P Soltész; P Antal-Szalmás; G Szegedi; J H Cohen; R P Taylor; M Kávai
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.

Authors:  Y M Lucisano Valim; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

3.  Immunoglobulin isotype composition of circulating and intra-articular immune complexes in patients with inflammatory joint disease.

Authors:  A D Crockard; J M Thompson; M B Finch; T A McNeill; A L Bell; S D Roberts
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

4.  Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.

Authors:  D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Defect of a complement receptor 3 epitope in a patient with systemic lupus erythematosus.

Authors:  T Witte; F L Dumoulin; J E Gessner; J Schubert; O Götze; C Neumann; R F Todd; H Deicher; R E Schmidt
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

6.  The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes.

Authors:  C H Nielsen; S H Matthiesen; I Lyng; R G Leslie
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

7.  Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans.

Authors:  N Madi; J P Paccaud; G Steiger; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 8.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

9.  Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35).

Authors:  C-H Chen; I Ghiran; F J M Beurskens; G Weaver; J A Vincent; A Nicholson-Weller; L B Klickstein
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

10.  Fc receptor function and circulating immune complexes in gluten sensitive enteropathy--possible significance of serum IgA.

Authors:  B Lavö; B Nilsson; L Lööf; U R Nilsson; K N Ekdahl
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.